Cetrelimab
Cetrelimab is a biological therapy with 15 clinical trials. Currently 12 active trials ongoing. Historical success rate of 50.0%.
Success Metrics
Based on 1 completed trials
Phase Distribution
Phase Distribution
8
Early Stage
5
Mid Stage
2
Late Stage
Highest Phase Reached
Phase 3Trial Status & Enrollment
50.0%
1 of 2 finished
50.0%
1 ended early
12
trials recruiting
15
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
A Study of JNJ-1761981 in Participants With Solid Tumors
A Study of Pasritamig (JNJ-78278343) in Combination With Other Agents for Metastatic Prostate Cancer
A Study of TAR-200 in Combination With Cetrelimab Versus Concurrent Chemoradiotherapy in Participants With Muscle-invasive Bladder Cancer (MIBC) of the Bladder
A Study of TAR-200 in Combination With Cetrelimab, TAR-200 Alone, or Cetrelimab Alone in Participants With Non-Muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Intravesical Bacillus Calmette-Guérin Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy
A Study of JNJ-86974680 in Participants With Advanced Non-small Cell Lung Cancer
Clinical Trials (15)
A Study of JNJ-1761981 in Participants With Solid Tumors
A Study of Pasritamig (JNJ-78278343) in Combination With Other Agents for Metastatic Prostate Cancer
A Study of TAR-200 in Combination With Cetrelimab Versus Concurrent Chemoradiotherapy in Participants With Muscle-invasive Bladder Cancer (MIBC) of the Bladder
A Study of TAR-200 in Combination With Cetrelimab, TAR-200 Alone, or Cetrelimab Alone in Participants With Non-Muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Intravesical Bacillus Calmette-Guérin Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy
A Study of JNJ-86974680 in Participants With Advanced Non-small Cell Lung Cancer
A Study of TAR-200 in Combination With Cetrelimab or TAR-200 Alone Versus Intravesical Bacillus Calmette-Guérin (BCG) in Participants With BCG-naïve High-risk Non-muscle Invasive Bladder Cancer (HR-NMIBC)
A Study of Erdafitinib in Participants With Metastatic or Locally Advanced Urothelial Cancer
A Study of TAR-200 in Combination With Cetrelimab and Cetrelimab Alone in Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder
A Study of Combination Therapy With Amivantamab and Cetrelimab in Participants With Metastatic Non-small Cell Lung Cancer
A Study of JNJ-87704916, as Monotherapy and in Combination for Advanced Solid Tumors
CD8 PET Imaging in Metastatic Solid Tumours
Cabazitaxel, Carboplatin, and Cetrelimab Followed by Niraparib With or Without Cetrelimab for the Treatment of Aggressive Variant Metastatic Prostate Cancer
A Study of Tolododekin Alfa (ANK-101) in Combination With an Anti-PD-1/PD-L1 Antibody in Participants With Advanced Non-Small Cell Lung Cancer
Apalutamide Plus Cetrelimab in Patients With Treatment-Emergent Small Cell Neuroendocrine Prostate Cancer
A Study of Cetrelimab in Participants With Chronic Hepatitis B Virus Infection
All 15 trials loaded
Drug Details
- Intervention Type
- BIOLOGICAL
- Total Trials
- 15